BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18421057)

  • 1. Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
    Zota V; Miron PM; Woda BA; Raza A; Wang SA
    J Clin Oncol; 2008 Apr; 26(12):2040-1. PubMed ID: 18421057
    [No Abstract]   [Full Text] [Related]  

  • 2. Transient macular erythema with eosinophilia in a patient carrying the FIP1L1-PDGFRA fusion gene.
    Yahara H; Satoh T; Hashimoto T; Yokozeki H
    Br J Dermatol; 2007 Dec; 157(6):1284-7. PubMed ID: 17916194
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
    Shah S; Loghavi S; Garcia-Manero G; Khoury JD
    J Hematol Oncol; 2014 Mar; 7():26. PubMed ID: 24669761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene.
    Sorour Y; Dalley CD; Snowden JA; Cross NC; Reilly JT
    Br J Haematol; 2009 Jul; 146(2):225-7. PubMed ID: 19466970
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
    Helbig G; Kyrcz-Krzemien S
    Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
    [No Abstract]   [Full Text] [Related]  

  • 6. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
    Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
    [No Abstract]   [Full Text] [Related]  

  • 7. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.
    Tefferi A; Lasho TL; Brockman SR; Elliott MA; Dispenzieri A; Pardanani A
    Haematologica; 2004 Jul; 89(7):871-3. PubMed ID: 15257945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
    Coltro G; Santi R
    Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
    [No Abstract]   [Full Text] [Related]  

  • 9. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
    Lv Y; Yao X; Ling Q; Suo S; Wang J; Zhao S; Gao X; Tong H; Jin J; Zhang X; Yu W
    Ann Hematol; 2024 Jan; 103(1):357-360. PubMed ID: 37777636
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
    Srinivasan A; Scordino T; Baker A
    J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
    [No Abstract]   [Full Text] [Related]  

  • 11. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
    Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
    Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
    Pardanani A; Brockman SR; Paternoster SF; Flynn HC; Ketterling RP; Lasho TL; Ho CL; Li CY; Dewald GW; Tefferi A
    Blood; 2004 Nov; 104(10):3038-45. PubMed ID: 15284118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocarditis, kidney injury, and hypereosinophilia: FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasm with eosinophilia.
    Reid SE; Patel SA
    Blood; 2021 Sep; 138(12):1086. PubMed ID: 34554219
    [No Abstract]   [Full Text] [Related]  

  • 14. The molecular anatomy of the FIP1L1-PDGFRA fusion gene.
    Walz C; Score J; Mix J; Cilloni D; Roche-Lestienne C; Yeh RF; Wiemels JL; Ottaviani E; Erben P; Hochhaus A; Baccarani M; Grimwade D; Preudhomme C; Apperley J; Martinelli G; Saglio G; Cross NC; Reiter A;
    Leukemia; 2009 Feb; 23(2):271-8. PubMed ID: 18987651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
    Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
    Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.
    Ohnishi H; Kandabashi K; Maeda Y; Kawamura M; Watanabe T
    Br J Haematol; 2006 Sep; 134(5):547-9. PubMed ID: 16856885
    [No Abstract]   [Full Text] [Related]  

  • 17. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia.
    Monma F; Nishii K; Lorenzo F; Usui E; Ueda Y; Watanabe Y; Kawakami K; Oka K; Mitani H; Sekine T; Tamaki S; Mizutani M; Yagasaki F; Doki N; Miyawaki S; Katayama N; Shiku H
    Eur J Haematol; 2006 Jan; 76(1):18-22. PubMed ID: 16343267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia.
    Buijs A; Bruin M
    Leukemia; 2007 May; 21(5):1104-8. PubMed ID: 17301809
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
    Miyazawa K; Kakazu N; Ohyashiki K
    Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.